CLSD - Clearside Biomedical, Inc.

NasdaqGM - NasdaqGM Real Time Price. Currency in USD
Currency in USD

Valuation Measures

Market Cap (intraday) 5120.8M
Enterprise Value 392.75M
Trailing P/E N/A
Forward P/E 1-5.44
PEG Ratio (5 yr expected) 1N/A
Price/Sales (ttm)462.85
Price/Book (mrq)11.48
Enterprise Value/Revenue 3355.37
Enterprise Value/EBITDA 6-1.81

Trading Information

Stock Price History

Beta (5Y Monthly) 0.11
52-Week Change 385.91%
S&P500 52-Week Change 321.25%
52 Week High 34.1300
52 Week Low 30.5600
50-Day Moving Average 32.7709
200-Day Moving Average 31.5802

Share Statistics

Avg Vol (3 month) 31.34M
Avg Vol (10 day) 3649.41k
Shares Outstanding 544.41M
Float 27.44M
% Held by Insiders 19.34%
% Held by Institutions 138.60%
Shares Short (Jan 30, 2020) 42.4M
Short Ratio (Jan 30, 2020) 41.35
Short % of Float (Jan 30, 2020) 47.22%
Short % of Shares Outstanding (Jan 30, 2020) 45.40%
Shares Short (prior month Dec 30, 2019) 41.51M

Dividends & Splits

Forward Annual Dividend Rate 4N/A
Forward Annual Dividend Yield 4N/A
Trailing Annual Dividend Rate 3N/A
Trailing Annual Dividend Yield 3N/A
5 Year Average Dividend Yield 4N/A
Payout Ratio 40.00%
Dividend Date 3N/A
Ex-Dividend Date 4N/A
Last Split Factor 2N/A
Last Split Date 3N/A

Financial Highlights

Fiscal Year

Fiscal Year Ends Dec 30, 2018
Most Recent Quarter (mrq)Sep 29, 2019


Profit Margin 0.00%
Operating Margin (ttm)-19,740.61%

Management Effectiveness

Return on Assets (ttm)-67.62%
Return on Equity (ttm)-183.18%

Income Statement

Revenue (ttm)261k
Revenue Per Share (ttm)0.01
Quarterly Revenue Growth (yoy)N/A
Gross Profit (ttm)30k
EBITDA -51.31M
Net Income Avi to Common (ttm)-49.31M
Diluted EPS (ttm)-1.3860
Quarterly Earnings Growth (yoy)N/A

Balance Sheet

Total Cash (mrq)22.55M
Total Cash Per Share (mrq)0.55
Total Debt (mrq)11.61M
Total Debt/Equity (mrq)118.93
Current Ratio (mrq)2.22
Book Value Per Share (mrq)0.24

Cash Flow Statement

Operating Cash Flow (ttm)-53.02M
Levered Free Cash Flow (ttm)-36.71M